Specialist in bioidentical peptides and hormone optimization Member of the American Academy of Aesthetic Medicine Expert in testosterone therapy and hormonal balance Dr
(PubMed) van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl H
ECC5004 (AZD5004) is currently in phase II trials, after achieving positive phase I trials
as of May 2026 is clinical trial enrollment FDA-approved alternatives exist (semaglutide, tirzepatide) with established compounding and dosing pathways and substantial clinical data Self-sourcing research peptides for human use is not safe and carries identity, purity, and contamination risks If you are a clinician: Patient questions about retatrutide source verification are increasing
Cardoso BR, Duarte GBS, Reis BZ, Cozzolino SMF, 2017
TSA permits injectable medications including GLP-1 compounds in both carry-on and checked luggage